Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | terminated | Phase 1 / Phase 2 | 60 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03016130 | Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | terminated | Phase 3 | 217 | University of FloridaOTHER | 1 | Apr 7, 2025 | clinicaltrials |
| NCT04185428 |
| Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia |
| terminated |
| N/A |
| 9 |
| University of FloridaOTHER |
| 1 |
| Apr 7, 2025 |
| clinicaltrials |
| NCT03038230 | MCLA-117 in Acute Myelogenous Leukemia | terminated | Phase 1 | 80 | Merus B.V.INDUSTRY | 5 | Apr 6, 2025 | clinicaltrials |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | terminated | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia(ENHANCE-3) | terminated | Phase 3 | 378 | Gilead SciencesINDUSTRY | 20 | Apr 4, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT03746054 | Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality(PALERMO) | terminated | Phase 3 | 80 | University Hospital, AngersOTHER_GOV | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)(R/R) | terminated | Phase 1 / Phase 2 | 1 | Aprea TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | terminated | Phase 1 | 36 | Aptose Biosciences Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04477291 | A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | terminated | Phase 1 | 45 | Aptose Biosciences Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT02291965 | Blood Samples to Identify Biomarkers of Busulfan | terminated | — | 139 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06110208 | Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML | terminated | Early Phase 1 | 3 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT03686345 | Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia(AML FLT3) | terminated | Phase 2 | 34 | Niguarda HospitalOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04905407 | Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 66 | Syros PharmaceuticalsINDUSTRY | 2 | Feb 24, 2025 | clinicaltrials |
| NCT05348889 | First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 7 | Chimagen Biosciences, LtdINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04778397 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated(ENHANCE-2) | terminated | Phase 3 | 258 | Gilead SciencesINDUSTRY | 15 | Feb 5, 2025 | clinicaltrials |
| NCT04342962 | Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia | terminated | Phase 2 | 25 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT01743807 | Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia | terminated | Phase 1 | 4 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | terminated | Phase 1 | 16 | Lava TherapeuticsINDUSTRY | 4 | Jan 27, 2025 | clinicaltrials |
| NCT02398825 | Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | terminated | Phase 2 | 14 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04914676 | Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission | terminated | Phase 2 | 5 | University of FloridaOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT04305444 | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | terminated | Phase 2 | 55 | Zhejiang DTRM BiopharmaINDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | terminated | Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia(UNITY-CLL) | terminated | Phase 3 | 603 | TG Therapeutics, Inc.INDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT04310592 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML(CYNK001AML01) | terminated | Phase 1 | 27 | Celularity IncorporatedINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05350163 | T-cell Receptor α/β Depleted Donor Lymphocyte Infusion | terminated | Phase 1 | 11 | Guenther KoehneOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04282668 | A Study of TAS1440 With ATRA in Subjects With r/r AML | terminated | Phase 1 | 52 | Taiho Oncology, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04582864 | Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | terminated | Phase 2 | 11 | Washington University School of MedicineOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT04340154 | Study of Sequential CAR-T Cell Treating Leukemia Children | terminated | Phase 2 | 81 | Beijing Boren HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04755244 | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | terminated | Phase 1 | 14 | ALX Oncology Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05032599 | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 19 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT04762875 | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies | terminated | Phase 2 | 7 | EnsomaINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05601466 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT02610062 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 23 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 1, 2024 | clinicaltrials |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | terminated | Phase 1 / Phase 2 | 46 | GenmabINDUSTRY | 5 | Oct 24, 2024 | clinicaltrials |
| NCT02864290 | A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 43 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Oct 23, 2024 | clinicaltrials |
| NCT02270463 | SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission | terminated | Phase 1 / Phase 2 | 16 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03541369 | Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia(20170528) | terminated | Phase 1 | 64 | AmgenINDUSTRY | 6 | Oct 10, 2024 | clinicaltrials |
| NCT03735875 | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | terminated | Phase 1 | 7 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05094206 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | terminated | Phase 1 | 4 | Medical College of WisconsinOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05682170 | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 40 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03154827 | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 1 | BioLineRx, Ltd.INDUSTRY | 6 | Sep 5, 2024 | clinicaltrials |
| NCT03603964 | Guadecitabine Extension Study | terminated | Phase 2 | 35 | Astex Pharmaceuticals, Inc.INDUSTRY | 9 | Aug 27, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 10, 2025source: clinicaltrials